| Date | Title | Description |
| 01.04.2025 | Immunovia's Warrant Series TO 3: A Crucial Step for Investors and Patients Alike | Immunovia AB, a beacon of hope in the fight against pancreatic cancer, has launched the exercise period for its warrants series TO 3. This event, commencing on April 1, 2025, is not just a routine financial maneuver; it’s a pivotal moment f... |
| 01.04.2025 | The exercise period for warrants series TO 3 begins today | The exercise period for warrants series TO 3 begins today
Tue, Apr 01, 2025 08:30 CET Report this content
Today, 1 April 2025, the exercise period for warrants series TO 3 in Immunovia AB (publ) (“Immunovia” or the “Company”) (the “Warrant ... |
| 27.03.2025 | Immunovia announces determined exercise price for warrants series TO 3 | Immunovia announces determined exercise price for warrants series TO 3
Thu, Mar 27, 2025 20:40 CET Report this content
Immunovia AB (publ) (“Immunovia” or the “Company”) hereby announces that the exercise price for warrants series TO 3 (the... |
| 02.01.2025 | The exercise period for warrants of series TO 2 beings today | The exercise period for warrants of series TO 2 beings today
Thu, Jan 02, 2025 08:30 CET Report this content
Immunovia AB (publ) (“Immunovia” or the “Company”) hereby announces that today, 2 January 2025, the exercise period for warrants of... |
| 27.12.2024 | Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
Fri, Dec 27, 2024 23:45 CET Report this content
Immunovia AB (publ) (“Immunovia” or the “Company”) hereby announc... |
| 02.12.2024 | Last day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 2024 | Last day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 2024
Mon, Dec 02, 2024 09:30 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIREC... |
| 21.11.2024 | ExpreS2ion Biotechnologies: Full commitments from members of ExpreS2ion's Board and Management holding warrants of series TO 10 | ExpreS2ion Biotechnologies: Full commitments from members of ExpreS2ion's Board and Management holding warrants of series TO 10
Thu, Nov 21, 2024 08:45 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART... |
| 20.11.2024 | ExpreS2ion Biotechnologies: ExpreS2ion announces the start of the exercise period for warrants of series TO 10 | ExpreS2ion Biotechnologies: ExpreS2ion announces the start of the exercise period for warrants of series TO 10
Wed, Nov 20, 2024 08:30 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR IND... |
| 15.11.2024 | ExpreS2ion and Evaxion: A New Dawn for CMV Vaccines | In the world of biotechnology, breakthroughs often feel like whispers in a storm. Yet, the recent collaboration between ExpreS2ion Biotech and Evaxion Biotech is a thunderclap. Their joint effort focuses on a vaccine for cytomegalovirus (CM... |
| 14.11.2024 | ExpreS2ion announces TO 10 warrant exercise price and start of exercise period | ExpreS2ion announces TO 10 warrant exercise price and start of exercise period
Thu, Nov 14, 2024 19:47 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED... |
| 12.11.2024 | Interim report January 1 – September 30, 2024 | Interim report January 1 – September 30, 2024
Tue, Nov 12, 2024 08:50 CET Report this content
January 1 – September 30, 2024
The third quarter in figures Net sales were TSEK 8,408 (7,248), +16%. The loss after tax was TSEK 17,753 (12,786). ... |
| 14.08.2024 | Navigating the Financial Waters: Avida and Immunovia's Recent Moves | In the ever-shifting landscape of finance, two companies, Avida Finans AB and Immunovia AB, have recently made significant strides. Their actions reflect a broader trend in the market, where companies seek to bolster their financial positio... |
| 12.08.2024 | Immunovia publishes prospectus in connection with forthcoming rights issue | Immunovia publishes prospectus in connection with forthcoming rights issue
Mon, Aug 12, 2024 11:50 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTR... |
| 26.06.2024 | Rights issue subscription period ending 27 June 2024; subscription possible via form | Rights issue subscription period ending 27 June 2024; subscription possible via form
Wed, Jun 26, 2024 09:00 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE ... |
| 17.06.2024 | The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17[th], 2024 | The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17[th], 2024
Mon, Jun 17, 2024 08:00 CET Report this content
Today, June 17th, 2024, is the last day for trading in Moberg Pharma AB's (publ)'s (&qu... |
| 13.06.2024 | Annual general meeting has been held in SciBase Holding AB (publ) | Annual general meeting has been held in SciBase Holding AB (publ)
Thu, Jun 13, 2024 16:15 CET Report this content
Today, the annual general meeting of 2024 was held in SciBase Holding AB (publ) (the “Company” or “SciBase”). Below follows a ... |
| 05.06.2024 | The exercise period for Moberg Pharma's warrants of series 2023:1 (TO 2) begins today | The exercise period for Moberg Pharma's warrants of series 2023:1 (TO 2) begins today
Wed, Jun 05, 2024 08:00 CET Report this content
Today, the exercise period for Moberg Pharma AB (publ)'s ("Moberg Pharma" or the "Company&q... |
| 31.05.2024 | Subscription price for Moberg Pharma's warrants of series 2023:1 (TO 2) determined | Subscription price for Moberg Pharma's warrants of series 2023:1 (TO 2) determined
Fri, May 31, 2024 20:00 CET Report this content
Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") today announces that the subsc... |
| 02.05.2024 | Last day of trading in unit rights in SciBase rights issue | Last day of trading in unit rights in SciBase rights issue
Thu, May 02, 2024 08:30 CET Report this content
Today, 2 May 2024, is the last day of trading in unit rights in SciBase Holding AB (publ) ("SciBase" or the "Company&q... |
| 23.04.2024 | Today is the first day of the subscription period in SciBase rights issue | Today is the first day of the subscription period in SciBase rights issue
Tue, Apr 23, 2024 08:00 CET Report this content
Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ("SciBase" or the "Company&q... |
| 19.04.2024 | SciBase publishes prospectus in connection with upcoming rights issue | SciBase publishes prospectus in connection with upcoming rights issue
Fri, Apr 19, 2024 14:15 CET Report this content
On 5 April 2024, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Board of Di... |
| 05.04.2024 | ChromoGenics AB (publ) announces allocation in directed share issue | ChromoGenics AB (publ) announces allocation in directed share issue
Fri, Apr 05, 2024 15:30 CET Report this content
On 5 March 2024 ChromoGenics AB (publ) ("ChromoGenics" or the "Company") announced that the Company's bo... |
| 05.03.2024 | CHROMOGENICS HAS SUCCESSFULLY COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 16 MILLION | CHROMOGENICS HAS SUCCESSFULLY COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 16 MILLION
Tue, Mar 05, 2024 21:40 CET Report this content
The board of directors of ChromoGenics AB (publ) (”ChromoGenics” or the ”Company”) has today, sub... |
| 17.01.2024 | InCoax publishes supplementary prospectus | InCoax publishes supplementary prospectus
Wed, Jan 17, 2024 14:45 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG,... |
| 08.01.2024 | WntResearch publishes prospectus in connection with rights issue | WntResearch publishes prospectus in connection with rights issue
Mon, Jan 08, 2024 12:16 CET Report this content
The board of directors of Wntresearch AB (“WntResearch” or the “Company”) has prepared an EU Growth Prospectus (the “Prospectus... |
| 08.01.2024 | InCoax publishes prospectus in connection with rights issue | InCoax publishes prospectus in connection with rights issue
Mon, Jan 08, 2024 16:30 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, ... |
| 21.06.2023 | CHROMOGENICS PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE | CHROMOGENICS PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE
Wed, Jun 21, 2023 19:44 CET Report this content
PRESS RELEASE
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED ... |
| 29.05.2023 | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31!
Mon, May 29, 2023 09:45 CET Report this content
It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of... |
| 11.04.2023 | Rights issue subscription period ending 12 April 2023; subscription possible via form | Rights issue subscription period ending 12 April 2023; subscription possible via form
Tue, Apr 11, 2023 12:15 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE... |
| 17.03.2023 | Immunovia publishes prospectus relating to the rights issue | Immunovia publishes prospectus relating to the rights issue
Fri, Mar 17, 2023 12:55 CET Report this content
NOT FOR PUBLICATION, RELEASE DISSEMINATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATE... |
| 09.01.2023 | The CEO applies for subscription of additional units in WntResearch’s ongoing rights issue with last day for subscription on 13 January 2023 | The CEO applies for subscription of additional units in WntResearch’s ongoing rights issue with last day for subscription on 13 January 2023
Mon, Jan 09, 2023 08:00 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIREC... |
| 22.12.2022 | Vator Securities chooses Bricknode to administer share issue services | Vator Securities chooses Bricknode to administer share issue services
Thu, Dec 22, 2022 08:00 CET Report this content
Vator Securities, a leading corporate finance and advisory service provider, has chosen Bricknode’s digital investment man... |
| 14.12.2022 | WntResearch publishes prospectus in connection with rights issue | WntResearch publishes prospectus in connection with rights issue
Wed, Dec 14, 2022 16:35 CET Report this content
The board of directors of Wntresearch AB (“WntResearch” or the “Company”) has prepared an EU Growth Prospectus (the “Prospectus... |
| 14.04.2022 | S2Medical AB (publ) publishes EU-growth prospectus in connection with the forthcoming rights issue of units | S2Medical AB (publ) publishes EU-growth prospectus in connection with the forthcoming rights issue of units
Thu, Apr 14, 2022 15:06 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIR... |
| 23.12.2021 | Cyxone publishes prospectus due to the upcoming rights issue | Cyxone publishes prospectus due to the upcoming rights issue Thu, Dec 23, 2021 10:21 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NE... |
| 05.10.2021 | SciBase to present at the Vator Healthcare Innovation Summit on October 7, 2021 | SciBase to present at the Vator Healthcare Innovation Summit on October 7, 2021 Tue, Oct 05, 2021 15:00 CET
SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CEO Simon Grant will ... |
| 30.09.2021 | AlzeCure presents at Vator Healthcare Innovation Summit on October 7 | AlzeCure presents at Vator Healthcare Innovation Summit on October 7 Thu, Sep 30, 2021 10:00 CET
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting ... |
| 24.09.2021 | Vator Securities: Unleashing a paradigm shift in early detection of pancreatic cancer | Vator Securities: Unleashing a paradigm shift in early detection of pancreatic cancer Fri, Sep 24, 2021 12:23 CET
Advancing into commercial phase, Immunovia has achieved a strong launch of its first product IMMray PanCan-d which was shortly... |
| 07.07.2020 | ALZECURE PHARMA AB (PUBL)
Vator Securities: No one-trick pony - advancing a novel platform-based CNS company | AlzeCure has with its seven-project portfolio multiple shots at goal where each, while early stage, represents a potential multibillion-dollar opportunity.
It goes without saying that the past year's achievements mark management's extensive... |
